Composition for improving intestinal beneficial bacteria and resisting fatigue and application thereof
Through herbal compositions such as Codonopsis pilosula and Akkermansia, and the abundance of Saccharomyces bacteria were promoted and the problems of weak research on physical fatigue and side effects of Western medicine were solved, and the effects of improving intestinal microbial diversity and enhancing immunity were achieved.
Patent Information
- Application Number
- CN202510583026.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-27
- Publication Date
- 2025-08-01
AI Technical Summary
Existing traditional Chinese medicine studies have weak research on relieving physical fatigue. Western medicine has side effects in the treatment of treatment, and intestinal flora disorders are related to decreased physical recovery ability. There is a lack of effective methods to improve intestinal flora diversity and beneficial bacterial abundance.
The composition of beneficial bacteria to improve the intestinal tract is composed of herbs such as Codonopsis pilosula, Poria cocos, yam, white lentils, lotus seeds, coix seeds, amomum villoss, platycodon, licorice, tangerine peel, etc., to promote the growth of Lactobacillaceae and Akkermansia and increase the abundance of the beneficial fungus Saccharomyces.
Improve the diversity of intestinal flora, enhance intestinal barrier function, improve the body's immunity, have the effects of alleviating or resisting fatigue, improve the structure of intestinal flora, improve the liver glycogen content, and reduce serum urea nitrogen and blood lactate content.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology. Background Art
[0002] Physical fatigue refers to the temporary decline in the body's function after continuous or high-intensity physical activities. Its occurrence is closely related to energy metabolism disorders, oxidative stress damage, and neuro-muscular regulation imbalance. In traditional Chinese medicine, it mostly belongs to the categories of "fatigue due to overwork", "consumptive disease", "five kinds of fatigue", etc. Its theoretical system can be traced back to "Huangdi Neijing". Traditional Chinese medicine believes that physical fatigue is a syndrome of "deficiency in origin and excess in superficiality", with the three viscera of the spleen, liver, and kidney as the core. Physical fatigue has now become a common health problem in society, especially prominent among people with high-pressure jobs and those who sit in the office for a long time. At present, Western medicine is the main means to relieve physical fatigue, but adverse reactions often occur during the treatment process. As a representative of traditional medicine, traditional Chinese medicine has fewer adverse reactions compared with Western medicine, so it has attracted more and more attention.
[0003] However, the current research on relieving physical fatigue by traditional Chinese medicine is still relatively weak. Recent studies have found that there is a significant correlation between intestinal flora disorder and the decline in physical recovery ability. Western medicine treatment mostly adopts the method of supplementing energy (such as vitamins, minerals, energy drinks, etc.). Although it can relieve fatigue in the short term, the action time is short, and there are certain side effects, such as dependence, gastrointestinal discomfort, intestinal flora disorder, etc. Therefore, improving the diversity of intestinal flora, increasing the abundance of beneficial bacteria, and enhancing the body's immunity are new ways to promote health and relieve or resist physical fatigue. Summary of the Invention
[0004] The technical problem to be solved by the present invention is to provide a composition for improving the anti-fatigue effect of intestinal beneficial bacteria and its application. The composition of the present invention can improve the diversity of intestinal flora, promote Lactobacillaceae and Akkermansia growth and increase the abundance of beneficial fungi Saccharomyces bacteria, which helps to enhance the body's immunity and has the effect of relieving or resisting fatigue.
[0005] To solve the above technical problems, the technical solution adopted by the present invention is: A composition for improving the anti-fatigue effect of intestinal beneficial bacteria, the raw materials are composed of the following substances in parts by weight: 2-6 parts of Codonopsis pilosula, 1-4 parts of Poria cocos, 2-6 parts of Dioscorea opposita, 1-4 parts of Dolichos lablab, 1-4 parts of Lotus seed, 2-6 parts of Coix lacryma-jobi, 0.5-1.5 parts of Amomum villosum, 1-2.5 parts of Platycodon grandiflorum, 1-2.5 parts of Glycyrrhiza uralensis, 1-2.5 parts of Citrus reticulata Blanco.
[0006] The preferred raw materials are composed of the following substances by weight parts: Codonopsis pilosula 3 - 5, Poria cocos 1 - 3, Dioscorea opposita 3 - 5, Dolichos lablab 1 - 3, Lotus seed 1 - 3, Coix lacryma-jobi 3 - 5, Amomum villosum 0.5 - 1, Platycodon grandiflorum 1 - 2, Glycyrrhiza uralensis 1 - 2, Citrus reticulata Blanco 1 - 2.
[0007] The further preferred raw materials are composed of the following substances by weight parts: Codonopsis pilosula 4.28, Poria cocos 2.14, Dioscorea opposita 4.28, Dolichos lablab 2.14, Lotus seed 2.14, Coix lacryma-jobi 4.28, Amomum villosum 0.85, Platycodon grandiflorum 1.42, Glycyrrhiza uralensis 1.42, Citrus reticulata Blanco 1.42.
[0008] The present invention also provides the application of the above composition in the preparation of a preparation for improving the intestinal flora structure and increasing the abundance of intestinal Akkermansia bacteria, Lactobacillus bacteria.
[0009] The present invention also provides the application of the above composition in the preparation of a preparation for relieving or resisting fatigue; after administering the preparation, the liver glycogen content in the subject increases, the serum urea nitrogen decreases, and the blood lactic acid content decreases.
[0010] The present invention also provides the application of the above composition in the preparation of a preparation for improving the richness and diversity of the intestinal mycobiota; after administering the preparation, the Shannon index and Simpson index in the subject increase.
[0011] Improving the richness and diversity of the intestinal mycobiota means that at the phylum level, the proportion of Basidiomycota ( Basidiomycota ) increases.
[0012] Improving the richness and diversity of the intestinal mycobiota means that at the genus level, the abundance of Saccharomyces bacteria increases.
[0013] The present invention also provides the application of the above composition in the preparation of a preparation for enhancing intestinal barrier function and improving intestinal immunity.
[0014] The beneficial effects produced by adopting the above technical scheme are as follows: The composition of the present invention can improve the diversity of the intestinal flora, promote the growth of Lactobacillaceae and Akkermansia and increase the abundance of beneficial fungi Abundance of Saccharomyces , which helps to improve the body's immunity and has the effect of relieving or resisting fatigue; it can also enhance the intestinal barrier function and improve intestinal immunity. Description of the Drawings
[0015] Figure 1 It is the anti-fatigue effect diagram of the composition of the present invention on each group of mice; (A) Swimming time; (B) Liver glycogen; (C) Blood urea nitrogen (BUN); (D) Blood lactic acid. The data are shown as mean ± standard deviation. Asterisk ( ) represents p < 0.05.
[0016] Figure 2 This is the effect diagram of the composition of the present invention on the intestinal flora; (A) pCoA diagram; (B) Alpha diversity analysis; (C) Rarefaction curve; (D) Phylum-level diagram; (E) Heatmap at the genus level; (F) Diagram at the genus level. In the figure, Z represents the normal group, L represents the low-dose group of Formula A, and T represents the positive control taurine group. (G-H) The total bacterial content and the abundance of Akk in the colon were measured by real-time fluorescence quantitative PCR. Data are shown as mean ± standard deviation. n = 3, compared with the CON group, indicates P < 0.05.
[0017] Figure 3 This is the effect diagram of the composition of the present invention on intestinal fungi; (A) pCoA diagram; (B) Rarefaction curve; (C) Alpha diversity analysis; (D) Phylum-level diagram; (E) Heatmap at the genus level. In the figure, Z represents the normal group, L represents the low-dose group of Formula A, and T represents the positive control taurine group.
[0018] Figure 4 This is the effect diagram of the composition of the present invention in improving the intestinal barrier; (A) H&E staining; (B) PAS staining and the number of goblet cells; (C-D) Immunohistochemical detection of the expression of ZO-1 and Occludin. In the figure, CON represents the normal group, A-L represents the low-dose group of Formula A, and Tau represents the positive control taurine group. Data are shown as mean ± standard deviation. n = 3, compared with the CON group, indicates P < 0.05. Detailed implementation manners Example 1
[0019] Materials and methods 1 Materials 1.1 Experimental animals Male C57BL / 6 mice, 6 weeks old, weighing (18 ± 2) g, were purchased from Beijing SPF Biotechnology Co., Ltd., license number: SCXK(Beijing)2024-0001. After purchase, they were adaptively raised in the Experimental Animal Center of Shanxi University of Traditional Chinese Medicine. All animals were placed in a SPF-level constant temperature (22 - 24°C) environment with a 12 / 12 h light / dark cycle and a living environment where food and water were freely available, and were approved by the Animal Experiment Ethics Committee of Shanxi University of Traditional Chinese Medicine.
[0020] 1.2 Experimental drugs Taurine (batch number: C15550690); Codonopsis pilosula; Poria cocos; Dioscorea opposita; Dolichos lablab; Lotus seed; Coix lacryma-jobi; Amomum villosum; Platycodon grandiflorum; Glycyrrhiza glabra; Citrus reticulata Blanco (all purchased from Beijing Tongrentang).
[0021] 1.3 Main instruments and equipment High-speed refrigerated centrifuge, lactic acid tester, fluorescence quantitative PCR instrument, multi-functional microplate reader, swimming tank, electronic balance, water bath.
[0022] 1.4 Experimental reagents Blood urea nitrogen (BUN) assay kit, hepatic glycogen assay kit, quantitative fluorescence PCR kit, lactic acid test strip.
[0023] 2. Methods 2.1 Animal grouping Male C57BL / 6 mice were randomly divided into 5 groups: blank control group (CON group, sterile water), positive control group (Tau group, taurine 0.426 g / kg), low-dose group of formula A (A-L group), medium-dose group of formula A (A-M group), and high-dose group of formula A (A-H group), with 20 mice in each group. The mice were fed adaptively for 1 week before the experiment. The CON group was gavaged with 0.1 mL of water every day, the A-L group, A-M group, and A-H group were respectively gavaged with low, medium, and high doses of formula A, the Tau group was gavaged with 0.426 g / kg of taurine every day, and gavage was continued for 30 days. The body weight was measured every 3 days, and the gavage volume was adjusted according to the change in body weight.
[0024] 2.2 Preparation of formula A The formula contains 10 kinds of herbs: Codonopsis pilosula, Poria cocos, Dioscorea opposita, Dolichos lablab, Lotus seed, Coix lacryma-jobi, Amomum villosum, Platycodon grandiflorum, Glycyrrhiza glabra, Citrus reticulata Blanco. The raw materials are provided by Beijing Tongrentang. The adult dosage of the raw medicinal materials was converted to the mouse dosage according to the body surface area algorithm. The dosage converted from the adult dose was the medium-dose group: Codonopsis pilosula 4.28 g / kg, Poria cocos 2.14 g / kg, Dioscorea opposita 4.28 g / kg, Dolichos lablab 2.14 g / kg, Lotus seed 2.14 g / kg, Coix lacryma-jobi 4.28 g / kg, Amomum villosum 0.85 g / kg, Platycodon grandiflorum 1.42 g / kg, Glycyrrhiza glabra 1.42 g / kg, Citrus reticulata Blanco 1.42 g / kg. Half of the dosage converted from the adult dose was the low dose, and twice was the high dose. The above dosages were all the daily dosages of mice.
[0025] 2.3 Experimental methods 2.3.1 Mouse load-bearing swimming experiment The load-bearing swimming experiment is an animal experiment model commonly used to evaluate anti-fatigue ability. The length of the swimming time directly reflects the endurance of the animal. The longer the swimming time, the stronger the anti-fatigue ability. Ten mice were selected from each group of 20. 30 minutes after the last administration of the test sample, the mice with a 5% body weight lead sheet attached to the root of the tail were placed in a swimming tank to swim. The water depth was not less than 30 cm, and the water temperature was 25°C ± 1.0°C. The time from the start of swimming to death of the mice was recorded, that is, the load-bearing swimming time of the mice.
[0026] 2.3.2 Determination of blood lactic acid Another ten mice were selected from each group of 20. Blood was collected 30 minutes after the last dosing. Then, they swam in water at 30°C without load for 10 minutes and then stopped. 20 μL of blood was collected before swimming and added to a lactic acid test strip, and a lactic acid tester was used for determination; 20 μL of blood was immediately collected after swimming and added to a lactic acid test strip, and a lactic acid tester was used for determination; 20 μL of blood was collected again 20 minutes after rest and added to a lactic acid test strip, and a lactic acid tester was used for determination. Finally, the area under the blood lactic acid curve at three time points was used to judge the difference.
[0027] 2.3.3 Determination of serum urea nitrogen 30 minutes after the last administration of the test sample, they swam in water at 30°C without load for 90 minutes, and blood was collected 60 minutes after rest. Approximately 0.5 mL of whole blood (without anticoagulant) was collected from the mice by eye socket extraction. It was placed in a 4°C refrigerator for about 3 hours. After the blood coagulated, it was centrifuged at 2000 r / min for 15 minutes, and the serum was taken for standby and determined by the diacetyl-oxime method.
[0028] 2.3.4 Determination of liver glycogen For the mice sacrificed in 2.3.3, the liver was taken, rinsed with physiological saline and then dried with filter paper. The liver was weighed, and the liver glycogen content was detected according to the instructions of the glycogen content detection kit (BC0345).
[0029] 2.3.5 Real-time quantitative fluorescence PCR DNA was isolated from mouse feces using a kit (Solarbio, product number: D2700), and the DNA concentration was measured with a photometer. Subsequently, DNA, ddH2O, forward primer, reverse primer and SuperReal PreMix Plus were combined in 8 consecutive wells and analyzed using real-time fluorescence quantitative PCR (Bio-Rad, USA).
[0030] 2.3.6 Determination of intestinal flora After the mice were raised for 4 weeks, feces were collected and sent to Shanghai Personal Biotechnology Co., Ltd. for determination in dry ice. The rest of the data processing was carried out in the Bioinformatics Cloud of Shanghai Personal Biotechnology Co., Ltd. (https: / / www.genescloud.cn / ).
[0031] 2.3.7 HE staining to observe the pathological morphological changes of the colon For the mice sacrificed at 2.3.3, a part of the colon tissue was quickly taken and fixed in 4% paraformaldehyde. After dehydration, clearing, wax infiltration, and embedding to make wax blocks, the wax blocks were cut into 3 μm thin sections with a microtome, and hematoxylin-eosin (H&E) staining was performed to observe the pathological changes of the colon tissue.
[0032] 2.3.8 Periodic acid-Schiff (PAS) staining Perform PAS staining on the goblet cells in the colon of mice. Observe and take images using a microscope.
[0033] 2.3.8 Immunohistochemistry (IHC) staining sections After dewaxing, hydration, antigen retrieval, primary antibody incubation, secondary antibody incubation, DAB color development, hematoxylin staining, and mounting, collect relevant parts of the samples and calculate the positive area ratio.
[0034] 2.4 Data processing The experimental data results were analyzed using IBM SPSS Statistics 27 statistical software, and graphs were made using GraphPad Prism 9 software. P<0.05 indicates significant differences in the data.
[0035] Results and analysis 1. Formula A improves physical fatigue in mice To evaluate the anti-fatigue effect of Formula A, we conducted a load-bearing swimming experiment. As expected, compared with the CON group, the positive control Tau group taking taurine could significantly prolong the forced swimming time of mice. The A-M group increased the forced swimming time, but it did not reach statistical significance (Appendix Figure 1 A). The forced swimming time of the A-L group was significantly longer (p<0.05). The load-bearing swimming times of the A-L group and the Tau group were 699 s and 415 s respectively, which were increased by 126.2% and 34.3% compared with the CON group respectively (Appendix Figure 1 A). These data indicate that in the mouse load-bearing swimming experiment, Formula A may have a better anti-fatigue effect than taurine.
[0036] Compared with the CON group, the hepatic glycogen contents of the Tau group, A-L group, and A-M group were significantly increased (Appendix Figure 1 B). The A-L group and the A-M group were increased by 28.0% and 20.1% respectively compared with the CON group. There was no obvious difference in the hepatic glycogen content between the A-H group and the CON group (P>0.05), but it still showed an increase. At the same time, compared with the CON group, the BUN contents of the A-M group and the A-H group were significantly decreased (Appendix Figure 1C). The blood lactic acid contents of the A-L group and the A-M group were significantly lower than those of the control group (Appendix Figure 1 D), and the decrease in LA in the A-L group was the most significant.
[0037] 2. The formula of group A improved the structure of the intestinal flora and increased the abundance of Akkermansia To further study the effect of the formula of group A on the intestinal flora, we collected mouse fecal samples, extracted DNA and performed microbial diversity sequencing analysis on the 16S rRNA gene fragment. Among them, the Observed Species index and the Chao1 index were higher in the low-dose group of the formula of group A than in the CON group, indicating that the richness of normal intestinal bacterial species in the low-dose group of the formula of group A increased (Appendix Figure 2 B). Beta diversity uses the evolutionary relationships and abundance information of each sample sequence to calculate the distance between samples to reflect whether there are significant differences in microbial communities between samples. Principal coordinate analysis (PCoA) is a commonly used analysis method for Beta diversity. The results of Beta diversity analysis showed that there was no obvious difference in the composition of intestinal microbial communities between the low-dose group of the formula of group A and the CON group (Appendix Figure 2 A); the flatness of the rarefaction curve reflects the influence of sequencing depth on the diversity of observed samples. The flatter the curve, the more sufficient the sequencing results are to reflect the diversity contained in the current samples (Appendix Figure 2 C). The above results indicate that the formula of group A can increase the richness and comprehensive diversity of normal intestinal bacterial species; the formula of group A did not change the normal intestinal microbial community.
[0038] After intervention with the formula of group A, changes occurred in the intestinal flora of mice. At the phylum level, the relative abundance of Verrucomicrobia in the low-dose group of the formula of group A was up-regulated compared with the CON group (Appendix Figure 2 D). At the genus level, the relative abundances of Lactobacillaceae and Akkermansia in the low-dose group of the formula of group A were up-regulated (Appendix Figure 2 E-F). Some studies have shown that increasing the abundance of Lactobacillaceae in the intestinal microbiota can increase the concentration of short-chain fatty acids in the intestine, which plays a positive role in regulating the intestinal flora; Akkermansia is a beneficial bacterium that can promote host metabolism and enhance the intestinal barrier. Among them, the increase in Akkermansia was the most obvious ( Figure 2 E). Further, real-time quantitative fluorescence PCR was used to detect the total bacterial abundance, and it was found that the total bacterial abundance in the experimental group of the formula of group A decreased, while the abundance of Akkermansia increased in the experimental group (Appendix Figure 2G-H). After the intervention of Formula A, the relative abundances of Lactobacillaceae and Akkermansia in the intestines of mice increased. Since these two beneficial bacteria have a positive effect on intestinal health, it is speculated that the increase in their relative abundances may be related to the anti-fatigue effect of Formula A.
[0039] 3. Effects of Formula A on intestinal fungi There were significant differences in the intestinal fungal microbial community compositions between the low-dose group of Formula A and the CON group, indicating that Formula A can improve the evolutionary similarity of the intestinal flora in mice and enable mice to establish a new intestinal fungal community environment (Appendix Figure 3 A). The Shannon index and Simpson index in the low-dose group of Formula A were higher than those in the CON group, suggesting that Formula A improved the richness and diversity of the intestinal fungal community in mice (Appendix Figure 3 C). The intestinal fungal community in the low-dose group of Formula A changed compared with that in the CON group. At the phylum level, the proportion of Basidiomycota in the low-dose group of Formula A increased; at the genus level, the low-dose group of Formula A increased the abundance of the beneficial fungus Saccharomyces (Appendix Figure 3 E). Saccharomyces is a commonly used probiotic in clinical practice and has the functions of anti-infection and enhancing the intestinal barrier.
[0040] 4. Formula A improves the intestinal barrier After clarifying the changes in the intestinal flora compositions of mice in different groups, in order to further explore the effects of A-L on the intestinal tissue morphology and related functions of mice, this study performed hematoxylin-eosin (H&E) staining and periodic acid-Schiff (PAS) staining analysis on the intestines of mice. The intestinal tissue structures of mice in each group were intact, the boundaries between the tissues of each layer were clear, and the glands in the mucosal layer were abundant, and there were no pathological changes (Appendix Figure 4 A). Compared with the CON group, the number of goblet cells in the intestines of mice in the A-L group increased, while the number of goblet cells in the Tau group did not change significantly (Appendix Figure 4 B). The increase in the number of goblet cells is usually regarded as an important indicator of the improvement of intestinal barrier function, suggesting that Formula A may have a repair or enhancement effect on intestinal barrier function. To further explore the protective effect of Formula A on the intestinal mucosal barrier of mice, this study used immunohistochemistry to detect the expressions of ZO-1 and Occludin in the colon tissue. Compared with the CON group, the protein expressions of Occludin and ZO-1 in the colon tissue of the A-L group were significantly increased, suggesting that Formula A can enhance the intestinal barrier function of mice and improve intestinal immunity. (Appendix Figure 4 C-D).
[0041] Conclusion The results of this study found that the formula of group A could prolong the weight-bearing swimming time of mice, reduce the content of blood lactic acid, increase the liver glycogen reserve level of mice, and enhance the fatigue tolerance of the body.
[0042] The formula of group A regulated the intestinal flora and increased the abundances of beneficial bacteria Akkermansia and Lactobacillus. The formula of group A could regulate the intestinal fungal community and increase the abundance of beneficial fungus Saccharomyces.
[0043] The formula of group A increased the number of goblet cells in the intestines of mice, enhanced the expression of Occludin and ZO-1 proteins in the colon tissues of mice, improved the intestinal barrier, and enhanced intestinal immunity.
[0044] Discussion The generation mechanisms of body fatigue mainly include the metabolite accumulation theory, energy consumption theory, and free radical theory. During anaerobic respiration of cells, lactic acid is produced during sugar metabolism, and the hydrolysis of protein metabolism is strengthened to produce ammonia, which forms urea through the hepatic circulation and finally forms BUN. The more these two products, blood lactic acid and BUN, accumulate in the body, the easier it is to produce fatigue. The results of this study found that the formula of group A could reduce the content of blood lactic acid and improve the fatigue tolerance of the body. According to the "energy consumption theory", at the beginning of exercise, glucose in cells is consumed, blood sugar decreases, and liver glycogen is quickly broken down into glucose and released into the blood to maintain blood sugar stability. When liver glycogen is insufficient, it will cause hypoglycemia and energy supply interruption, leading to body fatigue. The results of this study found that the formula of group A could increase the liver glycogen reserve level of mice and enhance the fatigue tolerance of the body.
[0045] The intestinal flora is called the "second genome" of the body, and the analysis of intestinal flora diversity has become a new perspective for studying health and diseases in recent years. Vigorous exercise produces excessive free radicals, causing exercise-induced oxidative stress damage, increasing the deposition of harmful metabolites, inducing fatigue aggravation, and may also lead to a decrease in intestinal flora diversity and an increase in the relative abundance of pathogenic bacteria. This invention found that the formula of group A could increase the diversity of intestinal flora, promote the growth of Lactobacillaceae and Akkermansia, and increase the abundance of beneficial fungus Saccharomyces, which helps to improve the body's immunity.
[0046] The intestinal barrier is primarily composed of mechanical, chemical, immune, and biological barriers, playing a crucial role in maintaining intestinal function and preventing the transfer of bacteria and endotoxins from the intestinal lumen into the bloodstream. The intestinal mechanical barrier, primarily composed of intestinal epithelial cells and intercellular tight junctions, is the most important "first line of defense" of the intestinal barrier. This study found that the number of intestinal goblet cells increased and their structure was intact in mice treated with AL. This suggests that Formula A has a repairing or enhancing effect on intestinal barrier function. Occludin is a key component of tight junctions, and ZO-1 is a scaffolding protein for tight junctions. Together, they form and maintain the integrity and stability of tight junctions. Damage to the intestinal barrier facilitates the entry of harmful substances such as bacteria, their metabolites, and endotoxins into the bloodstream, triggering systemic inflammation and potentially impacting brain function. This study showed significant increases in occludin and ZO-1 protein expression in the AL group, indicating that Formula A can enhance intestinal barrier function and improve intestinal immunity in mice. In summary, Formula A has the potential to become a new functional health product ingredient for combating fatigue, regulating intestinal flora, and strengthening the intestinal barrier.
Claims
1. A composition for improving the anti-fatigue effect of beneficial intestinal bacteria, characterized in that: The raw materials are composed of the following substances by weight parts: 2 - 6 parts of Codonopsis pilosula, 1 - 4 parts of Poria cocos, 2 - 6 parts of Dioscorea opposita, 1 - 4 parts of Dolichos lablab, 1 - 4 parts of Lotus seed, 2 - 6 parts of Coix lacryma-jobi, 0.5 - 1.5 parts of Amomum villosum, 1 - 2.5 parts of Platycodon grandiflorum, 1 - 2.5 parts of Glycyrrhiza uralensis, 1 - 2.5 parts of Citrus reticulata Blanco.
2. The composition according to claim 1, wherein: The raw materials are composed of the following substances by weight parts: 3 - 5 parts of Codonopsis pilosula, 1 - 3 parts of Poria cocos, 3 - 5 parts of Dioscorea opposita, 1 - 3 parts of Dolichos lablab, 1 - 3 parts of Lotus seed, 3 - 5 parts of Coix lacryma-jobi, 0.5 - 1 part of Amomum villosum, 1 - 2 parts of Platycodon grandiflorum, 1 - 2 parts of Glycyrrhiza uralensis, 1 - 2 parts of Citrus reticulata Blanco.
3. The composition according to claim 2, wherein: The raw materials are composed of the following substances by weight parts: 4.28 parts of Codonopsis pilosula, 2.14 parts of Poria cocos, 4.28 parts of Dioscorea opposita, 2.14 parts of Dolichos lablab, 2.14 parts of Lotus seed, 4.28 parts of Coix lacryma-jobi, 0.85 part of Amomum villosum, 1.42 parts of Platycodon grandiflorum, 1.42 parts of Glycyrrhiza uralensis, 1.42 parts of Citrus reticulata Blanco.
4. Use of the composition according to any one of claims 1 to 3 in the preparation of a preparation for improving the intestinal flora structure and increasing the abundance of Akkermansia bacteria and Lactobacillus bacteria in the intestine. Akkermansia bacteria Lactobacillus in the intestine.
5. Use of the composition according to any one of claims 1 - 3 in the preparation of a preparation for relieving or resisting fatigue.
6. The application according to claim 5, wherein: After administering the said preparation, the hepatic glycogen content in the subject's body increases, the serum urea nitrogen decreases, and the blood lactic acid content decreases.
7. Use of the composition according to any one of claims 1 - 3 in the preparation of a preparation for improving the richness and diversity of the intestinal fungal community.
8. The application according to claim 7, wherein: Improving the richness and diversity of the gut mycobiota means increasing the proportion of Basidiomycota ( Basidiomycota ) at the phylum level; and increasing the abundance of Saccharomyces fungi at the genus level.
9. The application according to claim 7, characterized in that: After administering the said preparation, the Shannon index and Simpson index in the subject's body increase.
10. Use of the composition according to any one of claims 1 - 3 in the preparation of a preparation for enhancing intestinal barrier function and improving intestinal immunity.